Navigation Links
Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Date:1/27/2011

CORK, Ireland, Jan. 27, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.  The generic pharmaceutical manufacturers in India will have rights to market the product in sub-Saharan Africa (SSA), Least Developed Countries (LDCs) and India. Aspen will have rights to market the product in SSA including South Africa. Under the agreement, the generic manufacturers will be entitled to manufacture once-daily 25 mg TMC278 as a single agent medicine and a fixed-dose combination (FDC) product. Fixed-dose combinations contain multiple medicines formulated into one tablet helping to simplify HIV therapy and are preferred by public health treatment programs. Tibotec has chosen to collaborate with multiple manufacturers in order to ensure the widespread and sustainable access to, and supply of, TMC278 in areas of high HIV burden and to support generic competition.    

Tibotec specializes in the research and development of new medicines for infectious diseases including HIV. It plays a key role in the Johnson & Johnson Global Access & Partnerships Program, which is committed to improving and saving lives by addressing unmet medical needs and ensuring the availability of HIV medicines to patients in need. The Program is already working, through existing agreements with generic manufacturers Aspen of South Africa and

SOURCE Tibotec Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
2. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
3. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
4. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
5. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
6. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
9. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
10. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
11. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014   BioNano Genomics announced today achievement of ... collect human data at 30X depth, sufficient for a genome ... capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s collaborators ... showcasing this advancement at the American Society for Human ...
(Date:10/20/2014)... 2014 Pharmaceutic Labs announces the opening of ... Albany, NY for admixing, compounding, drug shortages ... exceeds the FDA standards for safety and quality, using ... The 10,000 square foot outsourcing facility ... assurance and quality control. The company will produce sterile ...
(Date:10/19/2014)... 20, 2014 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer (CFO), has notified the Board of Directors of ... a new career opportunity as CFO of Severn Trent plc.  James ... company will commence a search for a new CFO immediately. ... has helped build and lead a high-quality finance team at Shire. ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... ANTONIO, Oct. 6 Nautilus Neurosciences, Inc., ... Pharmacal Company, a privately-held pharmaceutical company focused ... their exclusive co-promotion agreement for CAMBIA™ (diclofenac ... and other women,s health medical professionals. CAMBIA™ ...
... Gerresheimer Reports Strong Earnings and Sales Growth -- DUSSELDORF, Germany, October 6, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4Gerresheimer Reports Strong Earnings and Sales Growth 2Gerresheimer Reports Strong Earnings and Sales Growth 3Gerresheimer Reports Strong Earnings and Sales Growth 4Gerresheimer Reports Strong Earnings and Sales Growth 5Gerresheimer Reports Strong Earnings and Sales Growth 6Gerresheimer Reports Strong Earnings and Sales Growth 7Gerresheimer Reports Strong Earnings and Sales Growth 8Gerresheimer Reports Strong Earnings and Sales Growth 9
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... WASHINGTON, July 7 Cardinal Justin Rigali, Chairman of ... today to final guidelines for human embryonic stem cell ... (NIH). The text of his statement follows: , ... for destructive embryonic stem cell research, saying that under ...
... heart drugs get the wrong dose or end up on ... children, according to research led by the Johns Hopkins Children,s ... While the researchers found the highest number of ... children of all ages are vulnerable to such mistakes because ...
... -- Chemical dependency and recovery in patients and physicians ... editorials in the July 2009 issue of Mayo ... the immense challenges, including potential tragedies, of prescription chemical ... crucial overview, direction and optimism. Addiction to ...
... DVA ), a leading provider of kidney ... (CKD), today opened its 100th DaVita Academy - the ... new teammates (employees). On hand to participate and ... former United States Senator Paul Sarbanes and Congressman Elijah ...
... 7 DRINKiQ.com , Diageo,s cutting edge ... as the Most Outstanding Health and Wellness web site by ... was also named runner-up in the Education Category. Now ... excellence for communications professionals. The program is sanctioned by the ...
... Bonnie Yanelli ... ... a leading quality improvement and care management organization, named Bonnie Yanelli and Joseph Krolak as ... to increase KePRO,s market share and the company,s overall revenue. , , , , ...
Cached Medicine News:Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:Wrong dose of heart meds too frequent in children 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 3Health News:DaVita's Award-Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore, Maryland 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 3Health News:KePRO Names Two New Business Development Directors 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: